Exclusive: Europe to accelerate trials of gene-engineered COVID-19 vaccines - sources
Wednesday, 10 June 2020 European officials aim to speed up trials for coronavirus vaccines containing genetically modified organisms, two EU sources told Reuters, in a move that could help shots developed by companies like AstraZeneca and Johnson & Johnson.
As many as 20 major EU banks are set to announce details for a new payments initiative in the very near future. This announcement came from Electronic Payments International. Business Insider reports the system is referred to as the Pan European Payment System Initiative (PEPSI). It will process card payments in addition to making fund transfers and mobile payments without using Mastercard's or Visa's network.
The UK left the European Union on January 31. Here we look at the latest figures and key dates in the ongoing Brexit process. Quote from Sarah Hewin, Chief economist at Standard Chartered, speaking to the Financial Times.
Credit: PA - Press Association STUDIO Duration: 00:48Published
The corporation behind Johnson's, Neutrogena, Clean & Clear, and more has just vowed to stop selling two lines of skin-care products used for skin-lightening overseas. On June 19, in the wake of the recent Black Lives Matter uprising, Johnson & Johnson said that it will cease production of two different lines from Asian and Middle Eastern markets that were used for skin-lightening lines.
Johnson & Johnson plans to start testing its coronavirus vaccine candidate in humans in July. The company said it will move up the timeline by about two months to start clinical trials. Previously the aim was to enter the clinic with the vaccine in September. The study will start in the second half of July and enroll 1,045 healthy volunteers in the US and Belgium. If the vaccine works, Johnson & Johnson has already pledged to distribute it at a nonprofit rate to help end the pandemic.
AstraZeneca expects to be able to deliver a billion doses of a possible COVID-19 vaccine this year and next if tests are successful, adding on Thursday it should shortly get results of an early stage clinical trial. Ciara Lee reports
A keenly-watched COVID-19 vaccine will be priced to allow as wide as possible access to it, if it proves successful, and will be made at huge scale to keep costs down and supply up, said the Oxford University professor co-leading its development. Emer McCarthy reports.
Jaipur: Rajasthan's Health Department has served a notice to NIMS hospital here seeking an explanation on conducting trials of Patanjali Ayurved's drug Coronil... Mid-Day Also reported by •Reuters India •IndiaTimes